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Abstract: Emphysema is mainly caused by cigarette smoking and is characterized by the 
loss of alveolar integrity and an enlargement of the alveolar space. However, mechanisms 
involved in its development are not fully understood. Alveolar cell apoptosis has been 
previously investigated in the lung of emphysematous subjects as a potential contributor 
to the loss of alveolar cell and has been found abnormally elevated. Though, mechanisms 
involved in the increased alveolar apoptosis that occurs in emphysema have now become a 
proliﬁ  c ﬁ  eld of research. Those mechanisms are reviewed here with special focus on how 
they affect cell viability and how they may be implicated in emphysema. Moreover, we sug-
gest a model that integrates all those mechanisms to explain the increased alveolar apoptosis 
observed in emphysema. This review also includes some reﬂ  ections and suggestions on the 
research to come.
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Introduction
According to the World Health Organization, chronic obstructive pulmonary disease 
(COPD) is believed to become the third cause of death by 2030 with cigarette smok-
ing as the main cause.1 COPD features two main phenotypes: chronic bronchitis and 
emphysema with different physiopathology and symptoms. Emphysema has retained 
attention for its micro- and macroscopical manifestations: the loss of alveolar integ-
rity and an enlargement of the alveolar space.2 This leads to a poor gas exchange 
at the alveolar level and to the retention of air caused by airways collapse due to 
the loss of elastic recoil (hyperinﬂ  ation).2 But what is literally destructing the lung 
parenchyma of emphysematous patients? Proteases have been blamed very early, as 
deﬁ  ciency in α1-antitrypsin (A1AT), the most important antiprotease of the lung, 
causes noxious gas-independent emphysema at an early age.3 Emphysema was ﬁ  rst 
considered a neutrophilic disease, neutrophils being the major protease generator 
of all immune cells.4 However, as research progressed, emphysema was revealed to 
be a much more complex disease also involving alveolar macrophages (AM)5 and 
cytotoxic CD8+ T lymphocytes (CTL).6 Therefore, emphysema is now considered 
a complex inﬂ  ammatory disease with only partly understood physiopathology. But 
the question remains: why and how alveolar structure is disappearing? Recently, 
new hypothesis rose trying to answer this question, among those was “apoptosis”, 
a complex and well-regulated process that leads to cell death. In this review, we 
will focus on the recent developments made on the involvement of apoptosis in 
emphysema and on the possible molecular mechanisms involved in the initiation 
and progression of the disease.International Journal of COPD 2009:4 20
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What we know
Apoptosis
Mechanisms involved in the programmed cell death are very 
complex but quite well described. There are many reasons 
why a cell would undergo apoptosis, among them: growth 
factor deprivation, mitotic aberrations, loss of contact with 
the extracellular matrix, direct induction by immune cells, 
activation of death receptors by soluble death ligands, and 
heavy damages caused by various stresses. All these “stimuli” 
will lead to cell apoptosis but will trigger different intracel-
lular pathways to achieve their goal. The two main apoptotic 
pathways are the extrinsic and the intrinsic pathways, both 
leading to DNA fragmentation and cell death.
The extrinsic pathway
The extrinsic pathway (Figure 1) is triggered mostly by death 
ligands such as tumor necrosis factor (TNF), Fas ligand 
(FasL), and TNF-related apoptosis-inducing ligand (TRAIL) 
through their respective receptors.7 Brieﬂ  y, the intracellular 
death domains of those receptors will, after autophosphoryla-
tion, recruit various adaptor molecules such as Fas-associated 
death domain (FADD). If all recruiting steps are encountered, 
procaspase-8/10 will be cleaved into their active form, 
caspase-8/10. Caspases (cystein-aspartase) are cystein pro-
teases found in their pro-form (inactive form) in living cells. 
Following speciﬁ  c cleavage, they will acquire their protease 
activity and will start to cleave speciﬁ  c substrates and activate 
other caspases. Once cleaved, those substrates will transmit 
the apoptotic signal to the nucleus or mitochondria (caspase-
3, 6, 7) or interfere with the anti-apoptotic protection (cellular 
FLICE-like inhibitory protein [cFLIP]). In addition, cleavage 
of the BH3-interacting domain death agonist (Bid) to trun-
cated Bib (tBid) will activate the intrinsic pathway.
The intrinsic pathway
The intrinsic pathway (Figure 1) is mainly triggered by 
cellular stresses that cause DNA damages like oxidative 
stress or UV light.8 Brieﬂ  y, DNA damages will lead to the 
tumor suppressor p53 activation, stabilization, and to the 
acquisition of its transcription factor activity. Among its 
targets, p53 will either induce cell-cycle associated genes 
(eg, p21, 14-3-3σ) or apoptosis-related genes (eg, Bax 
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[Bcl-2–associated X protein], NOXA [Latin for damage], 
PUMA [p53 upregulated modulator of apoptosis], Fas, 
TRAIL-R1/2) transcription, depending on the DNA dam-
age severity. If damages are too severe, p53 will lead to 
apoptosis: Bax, NOXA, and PUMA will massively trans-
locate to the mitochondria outer-membrane and facilitate 
the formation of channels that will allow pro-apoptotic 
factors to move to cytoplasm (DNAse, cytochrome c, and 
anti-apoptotic factors inhibitors). Cytochrome c will join 
Apaf-1 and caspase-9 to form the so-called apoptosome 
(activated caspase-9) that will activate caspase-3. As 
mentioned earlier, the extrinsic pathway can also activate 
the intrinsic pathway through Bid cleavage (tBid) by 
caspase-8/10, and help cytosolic Bax to translocate to the 
mitochondria and induce the release of the mitochondria-
contained apoptosis factors.
Finalities
No matter how apoptosis is induced or which pathway 
is involved, the ﬁ  nalities will be very similar.9 The most 
obvious observation is the dynamic membrane blebbing 
that precedes apoptotic bodies formation. Moreover, the 
membrane lipid phosphatidyl serine (PS) normally localized 
on the cytoplasmic side of the cell membrane will be exter-
nalized and used by scavenger cells to recognize apoptotic 
cells, leading to efﬁ  cient cell clearance. DNA will also be 
affected, with features like chromatid condensation, its 
fragmentation into 180–200 bp fragments (endonuclease 
G [Endo G], apoptosis-inducing factor [AIF]), and redis-
tribution of the genetic material into the forming apoptotic 
bodies (Rho kinase [ROCK]). All those changes will lead to 
a clean cell death without intracellular material loss and to 
the phagocytosis of apoptotic bodies by immune or adjacent 
structural cells.
Apoptosis and emphysema: cellular mechanisms
Presence of higher apoptosis level in the human emphysema-
tous lung has been reported numerous times in previous years 
(Table 1) and has been associated to decreased alveolar sur-
face area,10 but also to increased alveolar cell proliferation,11 
suggesting that regeneration processes of the emphysematous 
lung might be overwhelmed by its destruction or impared 
by unknown mechanisms. To explain this phenomenon, 
mechanisms involved in the regulation of cell survival and 
cell death have been studied in vivo (animal models, see 
Table 2), ex vivo, and in vitro. Here, we are summarizing the 
main mechanisms and their impacts on alveolar apoptosis 
that occurs in emphysema.
Protease-induced apoptosis
What are proteases?
Proteases are proteins able to cleave speciﬁ  c amino-acid 
sequences and are implicated in many biological processes. 
In the lung, as in other tissues, proteases activity is closely 
controlled by anti-proteases. Though, protease/anti-protease 
balance is an extremely important factor for tissue 
homeostasis.
What is known about proteases in apoptosis?
In addition to their role in protein turnover, cell migration, 
and lung immunity, it has been shown that proteases can 
also induce lung epithelial and endothelial cell apoptosis 
(Figure 2).12–14 In fact, Suzuki and colleagues14 showed 
that leukocyte elastase (LE), mainly released by activated 
polymorphonuclear leucocytes, can induce small airway 
and alveolar epithelial cell apoptosis through the intrinsic 
pathway and by decreasing AKT phosphorylation (anti-
apoptotic factor) following proteinase-activated receptor 1 
(PAR-1) activation. Yang and colleagues12 also demonstrated 
a similar effect of neutrophil elastase (NE) and proteinase 3 
(PR3), mainly secreted by activated neutrophils, on primary 
bovine arterial endothelial cells. On the other side, it has 
been demonstrated that the protease inhibitor α1-antitrypsin 
(A1AT) may act as a survival factor by preventing lung 
endothelial cell death induced by staurosporine15 and ciga-
rette smoke16 through active caspase inhibition. Moreover, 
increasing evidences suggest that “tissues inhibitor of 
metalloproteinases-1” (TIMP-1) may act as a survival factor 
through CD63-mediated extracellular signal-regulated kinase 
(ERK) and AKT activation.17 Taken together, these data 
suggest that protease/anti-protease imbalance can promote 
apoptosis both through direct activation of PAR-1 signaling 
and through the reduction of antiproteases’ ability to inhibit 
apoptotic processes.
What is known about proteases in promoting 
apoptosis in emphysema?
Discovering that A1AT deﬁ  ciency, the main inhibitor of 
NE, confers susceptibility to emphysema development18 and 
that emphysema-like changes can be induced by elastolytic 
enzymes instillation in animal models (elastase emphy-
sema)19 were at the fundaments of the protease hypothesis 
of emphysema development. In fact, proteases such as NE,20 
cathepsins L,21 and matrix metalloproteinases (MMP)-1,22,23 
-2,22,24 -8,22 -9,22,24 and -1225 are increased in the emphysema-
tous lung mainly due to a higher number of activated neu-
trophils and macrophages. The lung protease hyperactivity International Journal of COPD 2009:4 22
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is believed to affect alveolar integrity by degrading elastic 
ﬁ  bres responsible for the maintenance of alveolar structure 
and lung stretch. However, it seems that elastase-induced 
emphysema may not be attributable only to elastic ﬁ  bre 
degradation. In fact, elastase activity is detectable for only 
45 to 50 minutes after elastase instillation while emphysema 
phenotype and higher alveolar apoptosis remain for weeks,26 
probably due to the installation of an inﬂ  ammatory state. 
Supporting that hypothesis, mice knockout for IL-1β and 
TNF receptors gene and submitted to elastase instillation 
showed fewer emphysematous lesions as well as alveolar 
cells undergoing apoptosis,27 suggesting that elastase may 
promote disease progression and alveolar apoptosis through 
IL-1β and TNF-dependent mechanism. Moreover, in a mouse 
model of emphysema induced by local lung overexpression 
of interferon-γ, cathepsin S blockade, a protease involved 
Table 1 Characteristics of studies reporting elevated apoptosis in the emphysematous lung
Authors Studied group Control group Apoptosis detection 
technique
Apoptotic cell type
Segura-Valdez et al 200022 Smokers with emphysema Smokers and nonsmokers 
without COPD
In situ end labeling Mainly endothelial cells
Kasahara et al 200040 Smokers with emphysema Smokers and nonsmokers 
without emphysema
DNA fragmentation (TUNEL 
and LM-PCR) Single DNA 
detection (IHC)
Epithelial and 
endothelial cells
Yokohori et al 200411 Subjects with emphysema 
(smoking state not speciﬁ  ed)
Smokers and nonsmokers 
without emphysema
DNA fragmentation (TUNEL) Epithelial cells (mainly 
type II alveolar cells)
Calabrese et al 200597 Subjects with AAT-deﬁ  ciency 
emphysema
Young subjects with 
unspeciﬁ  ed smoking history
DNA fragmentation (TUNEL 
and agarose gel separation)
Alveolar wall cells
Imai et al 200510 Ex-smokers (6 months) 
with emphysema
Nonsmokers with 
unspeciﬁ  ed lung functions
cleaved caspase-3 and PARP 
(Western blot) and DNA 
fragmentation (agarose gel 
separation)
Not mentionned
Abbreviations: COPD, chronic obstructive pulmonary disease; IHC, immunohistochemistry; LM-PCR, ligation-mediated polymerase chain reaction; PARP, poly(ADP-ribose) 
polymerase; TUNEL, terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling.
Table 2 Animal models used to study apoptosis in emphysema
Authors Model of emphysema Apoptosis detection technique Apoptotic cell type
Kasahara et al 200040 Subcutaneaous injection of a VEGF 
receptor blocker (Sprague-Dawley rats)
DNA fragmentation (TUNEL and 
LM-PCR) Active caspase-3 (IHC)
Alveolar epithelial 
and endothelial cells
Lucey et al 200227 Intratracheal instillation of porcine 
pancreatic elastase (B6129SF2/J mice)
DNA fragmentation (TUNEL) Alveolar epithelial cells
Aoshiba et al 200398 Single intratracheal delivery 
of caspase-3 (C57BL/6 mice)
DNA fragmentation (TUNEL) 
and ssDNA detection (IHC)
Mainly alveolar epithelial cells
Bartalesi et al 200599 Whole-body exposure to cigarette 
smoke (C57BL/6 and DBA/2 mice)
DNA fragmentation (TUNEL) General increase but 
unspeciﬁ  ed cell type
Kuo et al 2005100 Whole-body exposure to cigarette 
smoke (Wistar rats)
DNA fragmentation (TUNEL) General increase but 
unspeciﬁ  ed cell type
Zheng et al 200528 Transgenic lung IFN-γ overexpression 
(CC10-rtTA-IFN-γ mice)
DNA fragmentation (TUNEL) Mainly alveolar Type I
and Type II cells
Petrache et al 2005101 Single intratracheal delivery of 
C12ceramide (C57BL/6 mice)
DNA fragmentation (TUNEL) Mainly endothelial cells but also 
Type II alveolar epithelial cells
Taraseviciene-Stewart 
et al 200585
Anti-endothelial cells immunization 
that triggered autoimmune response 
(Sprague-Dawley rats)
DNA fragmentation (TUNEL) 
and active caspase-3 (IHC)
Alveolar epithelial cells
Brass et al 2008102 Exposure to lipopolysaccharide 
(C57BL/6 mice)
DNA fragmentation (TUNEL) and 
active caspase-3 (Western blot)
Alveolar epithelial cells
Abbreviations: IFN, interferon; IHC, immunohistochemistry; LM-PCR, ligation-mediated polymerase chain reaction; TUNEL, terminal deoxynucleotidyl transferase biotin-dUTP 
nick end labeling; VEGF, vascular endothelial growth factor.International Journal of COPD 2009:4 23
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in the antigen presentation process, limited the increase of 
apoptosis,28 linking proteases once more with apoptosis in 
emphysema.
Decreased VEGF signaling
What is VEGF?
Vascular endothelial growth factor (VEGF) is a powerful 
angiogenic molecule with two receptors (VEGFR1 and 2) 
triggering opposite cell responses. VEGFR1 is mainly respon-
sible for the inhibition of endothelial cell migration and 
proliferation, when VEGFR2 tends to promote those 
processes. VEGF is found in great amount in the lung and 
act as a key factor in the endothelial maintenance.29
What is known about VEGF in apoptosis?
In regard to apoptosis and cell survival, it is known that 
VEGF, by itself, can inhibit serum deprivation-induced 
endothelial cell apoptosis in vitro.30,31 VEGF increases cell 
survival through phosphoinositide-3 kinase (PI3K)/Akt 
pathway activation32 leading to caspase-9 and Bad inac-
tivation33,34 and also by increasing the expression of the 
anti-apoptotic molecules Bcl-2, A1,30 survivin, and XIAP.35 
VEGF is also able to prevent ceramide-induced HMEC 
(human microvascular endothelial cells) apoptosis through 
MAPK/ERK pathway activation and SAPK/JNK pathway 
inhibition.31
What is known about decreased VEGF signaling 
in promoting apoptosis in emphysema?
The role of VEGF signaling in the emphysema pathophysiol-
ogy has raised signiﬁ  cant interest in the past years.36,37 It has 
been shown that VEGF and VEGFR2 levels were decreased 
in the lung of emphysematous subjects compared to healthy 
controls38 and were related to increased alveolar cell apop-
tosis.39 Cigarette smoke-exposed Sprague-Dawley rats also 
show decreased lung VEGF and VEGFR2.38 Moreover, rats 
treated with the VEGF receptor blocker SU5416 developed 
emphysema-like phenotype, condition that may be prevented 
by the administration of the caspase inhibitor Z-Asp-CH2-
DCB,40 suggesting that decreased VEGF signaling may 
induce apoptotic process leading to emphysema. In addition, 
SU5416 treated rats presented evidences of alveolar oxida-
tive stress (higher 8-hydroxyguanine and 4-hydroxynonenal 
staining).41 In this model, oxidative stress and emphysema 
may be prevented by the administration of the superoxyde 
dismutase mimic M40419,41 by N-acetylcystein (NAC),42 
and, interestingly, by the caspase inhibitor Z-Asp-CH2-
DCB,41 revealing that the apparition of oxidative stress is 
caspase-dependent. Taken together, these data suggest that 
decreased VEGF signaling may be responsible for endothelial 
cell apoptosis. However, the capillary bed appears essential 
for the growth and maintenance of alveolar septa.43 Moreover, 
as demonstrated in human fetal lung44,45 and in adult lung,46 
VEGF is released principally by respiratory epithelial cells. 
Therefore, it may lead to a potential vicious circle that will 
cause endothelial and epithelial cell apoptosis (Figure 3).
Oxidative stress
What is oxidative stress?
Basically, oxidative stress happens when a cell is exposed 
to molecules with important oxidative power such as free 
radicals. If the oxidative defenses are strong enough, cel-
lular damages will be negligible. However, if the oxidative 
aggression is too strong or if it persists for too long, cellular 
damages may then be very important.
What is known about oxidative stress in apoptosis?
It is well known that oxidative stress can trigger numerous 
cell responses, including the signaling cascade that will lead 
to apoptosis (through the intrinsic pathway), and many studies 
are available on the subject.47 In vitro, exogenous hydrogen 
peroxide (H2O2) or compounds that promote endogenous 
production of reactive oxygen species (ROS) (eg, arsenic tri-
oxide,48 anthracyclines,49 bleomycin,50 N-(4-hydroxyphenyl) 
retinamide51) are usually used to create oxidative stress. 
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In the majority of cell types, those treatments will trigger 
apoptosis through the intrinsic pathway as previously 
discussed (Figure 1).47 Another feature of oxidative stress-
induced apoptosis is the activation of the mitogen-activated 
protein kinase (MAPK) pathways ERK 1/2, jun N-terminal 
kinase (JNK), and p38 MAPK). The JNK pathway seems to 
be pro-apoptotic as its inhibition promotes survival in primary 
rat alveolar epithelial cells treated with H2O2.52 On the other 
side, ERK 1/2 and p38 MAPK tend to have important anti-
apoptotic effects as their inhibition impairs cell survival.52 
However, activation and cellular effects of MAPK pathways 
are known to be different according to cell types studied.
Main defenses against oxidative stress are antioxidant 
molecules and enzymes. The major antioxidants found in the 
lung are superoxide dismutase (superoxide anion scavenger), 
catalase (converts H2O2 to water), and glutathione peroxidase 
(converts organic hydroperoxides to organic hydroxides).53
What is known about oxidative stress in promoting 
apoptosis in emphysema?
In the case of emphysema, oxidant molecules have two 
main origins. The ﬁ  rst is of course cigarette smoke (active 
smoker), which contains free radicals with tremendous oxi-
dative power such as superoxide (O2•−), hydroxyl radical 
(•OH), and hydrogen peroxide (H2O2).54 It is important to 
note that nonemphysematous smokers are also exposed to 
the oxidative agents contained in cigarette smoke, suggesting 
that smokers who have developed emphysema (15%–20%) 
reacted differently or were more susceptible to this stress. 
The second source, and probably the most sustained, comes 
from the chronic inflammation inherent to emphysema 
that persists even after smoking cessation.55 Activated 
macrophages and neutrophils, present in higher number 
in the emphysematous lung,56–59 are powerful producers of 
reactive oxygen species (ROS).60,61 It is well known that the 
lung antioxidant defenses of subjects with emphysema are 
overwhelmed, leading to important oxidative damages. In 
fact, compared to those of normal smokers and ex-smokers, 
the emphysematous lung presents more damaged proteinsand 
more peroxidated lipids.62,63 All those oxidative damages 
may then lead to the increased alveolar apoptosis observed 
in emphysema (Figure 4).
TRAIL-mediated apoptosis
What is TRAIL?
Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) is a member of the death ligand TNF family that 
also includes FasL. TRAIL has four receptors: TRAIL-R1 
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Figure 3 Cigarette smoke (oxidative stress)-mediated VEGF signaling disruption leading to endothelial cell death, migration impairment, and general endothelium dysfunction 
causing epithelial cells apoptosis.
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and R2 which contain functional death domains, TRAIL-R3 
which contains a truncated death domain and acts as a decoy, 
and TRAIL-R4 which is unable to induce apoptotic signals 
but, as well as TRAIL-R1 and R2, can activate kinases that 
will lead to NF-κB activation.64
What is known about TRAIL in apoptosis?
First interest on TRAIL has been brought by its ability to 
induce transformed/cancer cell apoptosis while having no 
such effects on normal cells.65 Further research has shown 
that not all transformed/cancer cells were sensitive to its 
apoptotic signal.66 Interestingly, DNA damage and ROS 
generating agents are able to suppress cellular resistance 
to TRAIL-mediated apoptosis in many cell lines, including 
the lung adenocarcinoma cell line A549.67–69 Moreover, in a 
mouse model of Alzheimer’s disease, a disease characterized 
by a progressive lost of neuronal cells, blockade of TRAIL-
R2 prevents β-amyloid-induced neuronal cell apoptosis.70 
The main cells releasing TRAIL are activated macrophages, 
NK cells, and T lymphocytes.71–73
What is known about TRAIL in promoting apoptosis 
in emphysema?
TRAIL receptors 1, 2, and 3 have been shown to be upregu-
lated in the alveolar epithelial cells of emphysematous 
smokers and ex-smokers.74 Moreover, their expression was 
closely related to the levels of the tumor suppressor p53 in the 
emphysematous lung parenchyma.74 Interestingly, A549 cells 
(lung adenocarcinoma cell line) exposed in vitro to oxidative 
stress (H2O2) and TNF had higher expression of TRAIL-R1, 
2, and 3 but also higher levels of p53,74 suggesting that the 
modulation of the TRAIL system observed in the emphyse-
matous lung may be attributable to oxidative stress and/or 
inﬂ  ammatory cytokines. As TRAIL is released by activated 
inﬂ  ammatory cells, oxidative stress and inﬂ  ammation present 
in the emphysematous lung may sensitize alveolar cells to 
its apoptotic effects (Figure 5).
Killer cells and autoimmunity
What are killer cells and autoimmunity?
Killer cells are immune cells specialized in the act of killing 
infected or unwanted cells. There are mainly two types of 
killer cells: cytotoxic CD8+ T lymphocytes (CTL), members 
of the adaptive immunity, and natural killer (NK) cells, mem-
bers of the innate immunity. The main difference between 
these two cell types is the way they recognize cells that have 
to be killed. When a given cell is infected with intracellular 
pathogens, major histocompatibility complex (MHC) class 
I will present pathogen peptides at the cell surface allowing 
CTL to recognize it with their T cell receptor (TCR) and kill 
the infected cell.75 On its side, with no TCR, NK cell cannot 
use by itself antigen-based recognition to identify cells to be 
killed. However, speciﬁ  c antigen-mediated cytotoxicity can 
be indirectly induced through antibody-dependent cellular 
Figure 4 Increased alveolar apoptosis mediated through oxidative stress-induced cellular damages.International Journal of COPD 2009:4 26
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cytotoxicity (ADCC) via the binding of FcγRIII (CD16) to 
the Fc portion of IgG bound to speciﬁ  c target cell membrane 
antigen.76
Autoimmunity is an inappropriate immune response 
against antigens of the host (self-antigen) and can be trig-
gered by a variety of mechanisms;77 we describe here only 
those that may be relevant in emphysema. Autoimmune 
response can be triggered by modified self-antigen, as 
exposure of cells to agents that may affect protein integrity 
(eg, oxidants, proteases) can create molecules unknown to the 
immune system and cause autoimmune response. Moreover, 
molecules normally hidden from the immune system (located 
into the nucleus or the cytoplasm) may trigger autoimmune 
response if released. Failed clearance of apoptotic cells or 
high levels of necrosis may expose molecules normally 
sequestered to the cytoplasm or to the nucleus, as it is 
observed in systemic lupus erythematosus.78
What is known about killer cells and autoimmunity 
in apoptosis?
When an immune response is initiated against a self-antigen, 
processes involved in the targeting and recognition by 
antibodies or killer cells are very similar to those raised 
against pathogens. First, the humoral response is involved: 
subjects with autoimmune diseases like systemic lupus 
erythematosus and rheumatoid arthritis are presenting 
autoantibodies in their serum.79 Those antibodies secreted 
by activated B cells will, after recognition of their speciﬁ  c 
antigens, trigger local inﬂ  ammatory response to eliminate 
the cells that bears autoantigen/antoantibody complexes.80 
As mentioned earlier, NK cell can recognize these cells and 
induce their apoptosis. In fact, following recognition, NK cell 
will induce target cell’s apoptosis mainly trough the release of 
granules that contain cytotoxic molecules like “pore forming 
protein” (perforin), granzymes, and granulisin. Death ligands 
such as FasL and TRAIL also play an important role in the 
NK-mediated cell apoptosis.81 In addition to the antibody-
mediated immune response, a speciﬁ  c cellular response can 
be mediated by CD4+ and CD8+ T lymphocytes. Once CD4+ 
T lymphocytes have encountered their antigen presented by 
an antigen-presenting cell (APC) like dendritic cells, they 
will proliferate (oligoclonal expansion) and be involved in 
the activation of B cells and alveolar macrophages through 
cell/cell contact or the release of inﬂ  ammatory mediators.82 
On their side, activated CD8+ T lymphocytes will directly 
target cells that express the speciﬁ  c autoantigen and, with 
mechanisms similar to those used by NK cell, induce target 
cell apoptosis.83 All these processes will lead to the deletion 
of a speciﬁ  c autoantigen-bearing cell population.
What is known about killer cells and autoimmunity 
in promoting apoptosis in emphysema?
There are evidences that emphysema may have an autoim-
mune component. Autoreactive antibodies with avidity for 
pulmonary epithelial cells were found in the serum of about 
70% of subjects with emphysema when only 10% of normal 
smokers or nonsmokers were positive.84 Moreover, in vitro 
peripheral blood mononuclear cells cytotoxicity against pul-
monary epithelial cells was stronger in presence of plasma 
from emphysematous subjects than from normal subjects,84 
suggesting that autoreactive antibodies may initiate immune 
cell-mediated apoptosis. Moreover, a model of autoimmune 
emphysema (Table 2) revealed that immune response against 
lung endothelial cells can lead to alveolar endothelial and 
epithelial cell apoptosis and cause emphysema.85 Antibodies 
against elastin protein have also been found in the serum 
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of emphysematous subject86 as well as a higher number 
of B cells secreting anti-elastin antibodies in the emphy-
sematous lung.86 In the same study, they also found that 
peripheral blood CD4+ T lymphocytes from emphysematous 
subjects were releasing more gamma interferon (IFN-γ) and 
interleukin-10 (IL-10) than those from normal subjects upon 
in vitro elastin exposure.86 Oligoclonal CD4+ T lymphocytes 
able to proliferate in vitro upon interleukin-2 stimulation87,88 
as well as oligoclonal CD8+ T lymphocytes89 were found 
in the lung of subjects with emphysema. Moreover, CD8+ 
T lymphocytes from the lung of COPD subjects expressed 
higher levels of perforin and cytotoxic activity than those 
from controls,90.91 phenomenon that is not observed in the 
peripheral blood.92 All these data suggest the existence 
of a local antigen-driven cellular immunity in the lung of 
emphysematous subjects (Figure 6).
What we need to know
Which cell type is dying?
There are three major structural cell types in the alveolar 
tissue: Type I alveolar cells, Type II alveolar cells, and 
endothelial cells. Type I alveolar is the most abundant cell 
type found in the alveolar tissue. They are responsible for 
the maintenance of the alveolar structure and gas diffusion 
toward alveolar capillaries. Type II alveolar cells are the 
major source of surfactant proteins and are the progenitor of 
Type I alveolar cells. Endothelial cells are in charge of lung 
perfusion and, with Type I alveolar cells, of gas diffusion 
between alveoli and blood. As all these cell types are impor-
tant to maintain alveolar tissue integrity, the accelerated loss 
of one or another will have direct effect on the whole alveolar 
tissue. The technique of choice to detect apoptotic cells in the 
emphysematous lung is terminal deoxynucleotidyl transfer-
ase biotin-dUTP nick end labeling (TUNEL) analysis. Unlike 
tissue lysat-based analyses that only give a general view of 
the tissue apoptosis level (eg, Ligation-mediated polymerase 
chain reaction [LM-PCR], caspase-3 activity, poly(ADP-
ribose) polymerase [PARP]) cleavage), TUNEL allows a 
precise identiﬁ  cation of the cells that undergo apoptosis. 
However, despite comparative TUNEL analyses of normal 
and emphysematous lung (Table 1), no real consensus has 
been established on which cell type seems to die predomi-
nantly from apoptosis in the emphysematous lung.
According to the different hypothesis that attempt to 
explain the increased alveolar apoptosis that occurs in emphy-
sema, different cell types are targeted as the earliest cell type 
touched by apoptosis. The VEGF hypothesis points mainly 
at endothelial cells40 when the proteases imbalance,14,27 
oxidative stress,62 and TRAIL hypothesis74 tend to point at 
epithelial cells. Autoimmunity84,85 seems to be touching both 
endothelial and epithelial cells. If we consider the confor-
mation of the alveoli, epithelial alveolar cells are exposed 
directly to cigarette smoke and may be acting as a “cellular 
shield” for endothelial cells. It is then logic to assume that 
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most of the damages induced by cigarette smoke will be ﬁ  rst 
done to epithelial rather than endothelial cells. There is a lot 
of in vitro data on the effects of cigarette smoke on signal-
ing pathways of alveolar epithelial and endothelial cells. 
However, no data are currently available on the crosstalk 
of alveolar epithelial cells exposed to cigarette smoke with 
endothelial cells. This would be extremely relevant to under-
stand how damaged alveolar epithelial cells may affect the 
functions and the faith of endothelial cells, and would give 
important information on which cell type may be susceptible 
to undergo apoptosis ﬁ  rst.
When does it die?
Until now, publications on apoptosis in emphysema com-
pared the apoptosis levels in the lung of emphysematous 
subjects with well-developed disease with those of nonem-
physematous subjects. From this, we can say that apoptosis 
levels are higher in emphysematous subjects despite smoking 
cessation and we can suppose that apoptosis is involved in 
the progression of the disease. We also know that alveolar 
epithelial cells’ proliferation is increased, but does not seem 
to compensate for cell loss (apoptosis/proliferation imbal-
ance). However, we do not know if the apoptotic mecha-
nisms that have been described in this review are involved 
in the initiation of the disease or only in the progression 
once the disease has started. When does apoptosis overcome 
proliferation? When do proteases overcome anti-proteases? 
When do VEGF and VEGFR2 levels go down? When do 
p53, Bax/Bcl-xL ratio, and TRAIL-R go up? And ﬁ  nally, 
when does autoimmunity get in play? Answering these 
questions is not an easy task. In order to do so, we would 
need to study for a long period of time smoking subjects 
that are susceptible to develop emphysema but that have not 
developed it yet. However, since there is no reliable method 
to identify these subjects yet, animal models and in vitro 
cell culture are the only tools that can help to understand 
mechanisms involved in emphysema initiation rather than 
on its progression.
What is responsible for cell death?
Looking for only one mechanism to explain the increased 
alveolar apoptosis would be an important mistake. Prote-
ases, oxidative stress, decreased VEGF, autoimmunity, and 
TRAIL-mediated apoptosis are probably all involved at dif-
ferent levels in the increased apoptosis levels in emphysema. 
The elaboration of a complete model that would integrate all 
mechanisms and link them to each other may be extremely 
relevant to guide research on the increased apoptotic events 
observed in emphysema. Here, we propose a model (Figure 7) 
built from the studies we previously discussed. Emerging 
concepts or hypothesis such as alveolar apoptosis induced by 
neutrophils-derived defensins,93,94 link between innate immu-
nity and oxidative stress through Toll-like receptor 4 (TLR4) 
tone,95 and reduced or impared apoptotic cell clearance 
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(efferocytosis),96 even if very interesting and promising ways 
of research, were not included in the model.
Global model to explain increased apoptosis 
in emphysema
As we know, 90% of emphysema cases are developed follow-
ing cigarette smoke exposure. We also know that, among all 
its toxic power, cigarette smoke contains powerful oxidants. 
In some individuals with weaker oxidative defenses (genetic 
feature), chronic cigarette smoke exposure will lead to oxida-
tive defense depletion (see Arrow [1] in Figure 7) and the 
establishment of a sustained oxidative stress [2] leading to 
lethal injuries to alveolar cells [3] and an increase in alveolar 
cell apoptosis [4]. Oxidative stress can also be responsible for 
the initiation of an inﬂ  ammatory process, either from direct 
immune cell activation or through the release of inﬂ  amma-
tory mediators by injured alveolar cells [5]. In the present 
model, the following steps are very important to establish the 
chronic state of the disease. Activated inﬂ  ammatory cells, 
mainly neutrophils and macrophages, are well known to be 
powerful reactive oxygen species (ROS) producers [6]. ROS 
released from inﬂ  ammatory cells may then be involved in 
the establishment of a cigarette smoke-independent lung 
oxidative stress [7], as oxidative stress remains in the lung of 
emphysematous subjects after smoking cessation. Activated 
neutrophils and macrophages can also release great amount of 
proteases that then lead to lung protease/anti-protease imbal-
ance [8] and induce alveolar epithelial and endothelial apop-
tosis [9]. Protease hyperactivity and oxidative stress could 
also be responsible for the release of immunogenic peptides 
[10] and lead to the development of antigen-driven immune 
response (antigen-speciﬁ  c activation of B cells and CD4+ and 
CD8+ T cells) and then promote alveolar cell apoptosis [11]. 
Inﬂ  ammatory mediators, like TNF, and oxidative stress (cell 
injuries) can also modulate elements involved in alveolar cell 
sensitivity to TRAIL-mediated apoptosis (TRAIL receptors, 
p53, and Bax levels) [12] and switch alveolar cells from a 
TRAIL-mediated apoptosis resistant state to a sensitive state 
and lead to increased alveolar cell apoptosis [13]. Oxidative 
stress may also be responsible for the disruption of VEGF 
signaling [14], leading to alveolar endothelial cell apoptosis, 
and, through a lack of physical support, promoting alveolar 
epithelial cell apoptosis [15].
Based on this model of hypothesis, tools such as DNA 
and protein microarrays and softwares for cellular pathway 
interactions analysis will help to see in a more global way 
the pathways involved in the disease development while 
new primary cell isolation and culture will give better 
cellular models. All this will increase the comprehension of 
the different mechanisms involved in emphysema pathogen-
esis and ultimately lead the elaboration of treatments that will 
stop the development or the progression of the disease.
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